Recursion Pharmaceuticals

Recursion Pharmaceuticals Depreciation & Amortization

The Depreciation & Amortization of Recursion Pharmaceuticals (RXRX) as of Oct 30, 2026 is 18.80 M USD. In the previous year, Depreciation & Amortization was 8.50 M USD — a change of 121.18% (higher).

Depreciation & Amortization

18.80 MUSD

YoY

121.18%

Last updated:

Depreciation & Amortization of Recursion Pharmaceuticals is 2024 18.80 M USD. Depreciation & Amortization of Recursion Pharmaceuticals was 2023 8.50 M USD. It decreases by 121.18% higher compared to the previous year.

The Recursion Pharmaceuticals Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2021
300,000.00 USD
Jan 1, 2022
380,000.00 USD
Jan 1, 2023
8.50 M USD
Jan 1, 2024
18.80 M USD
The Recursion Pharmaceuticals Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
18.80 MUSD+121.18%
8.50 MUSD+2,136.84%
380,000.00USD+26.67%
300,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Depreciation & Amortization of Recursion Pharmaceuticals is 18.80 M USD in 2024.

Depreciation & Amortization of Recursion Pharmaceuticals changed from 8.50 M USD to 18.80 M USD, representing a 121.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals